|
Nanotechnology Colloquium
|
Colloquium Date: Monday, November 17, 2008
|
A bi-weekly event to present and discuss issues related to developments, applications and commercialization of nanotechnology.
Developing differentiated oncology drug products based on a superior nano-delivery technology
Michael T. Dwyer
President & CEO
AZAYA THERAPEUTICS, INC.
(VIDEO CONFERENCED FROM SAN ANTONIO)
Abstract:
Azaya, based in San Antonio, TX, is building a product pipeline around a novel and versatile nanotechnology drug delivery platform. Its patented (U.S. Patent No. 7,179,484) Protein Stabilized Nanoparticles (PSNTM) nanotherapy platform addresses the significant problems associated with the formulation and delivery of (1) water insoluble drugs, (2) radionuclides and (3) combination therapies.
The Company is initially applying its PSN nanotherapy platform to produce a targeted, safer and more efficacious formulation of TaxotereŽ (docetaxel), a marketed chemotherapy drug with worldwide annual sales in 2007 of $2.7+ billion, for the treatment of cancer. Beyond the Company's lead drug candidate, multiple additional water insoluble drug candidates have been identified and several are in the pre-clinical stages of development. To expand its product and intellectual property portfolios, Azaya recently licensed the patent rights from the University of Texas Health Science Center at San Antonio (UTHSCSA) for "Radiolabeled Compounds and Liposomes and Their Method of Making and Using Same". These radiation loaded liposomes are designed for use, initially, as an injection directly into tumor tissue. This product has application to treat many types of solid tumors including prostate cancer, breast cancer, rectal cancer and head and neck cancer, among others. This is a significant treatment advance designed to improve patient outcomes over current radiation practices both with external beam therapy and bracchytherapy.
Azaya has been funded by local investors with $7.3 million invested to date. The company recently applied to the Emerging Technology Fund of Texas for an investment of $1 million and will commence a new round of raising money in Q1 2009.
Bio: Michael T. Dwyer
Mr. Dwyer has 15 years experience in the biopharmaceutical industry working on the development of new drug compounds. He is a graduate of Angelo State University and spent 16 years and was an audit partner at Arthur Andersen & Co. Since he left public accounting, Mike has been involved in senior management roles at 4 start up companies that were sold to larger companies. He also spent 5 years at publicly traded ILEX Oncology, Inc. in senior management roles including CFO, CBO and COO. During this time ILEX developed 2 new chemotherapy products that were approved by the FDA prior to ILEX's sale to Genzyme Corporation in 2005. Mike joined Azaya in June 2005.
|
|
|
VENUE: You may attend the presentation from any
one of these law offices of Winstead PC or from UT Dallas
|
|
AUSTIN: Winstead PC
401 Congress Av., Ste 2100
Austin, TX 78701
512-370-2800
|
|
CHICAGO: NEW VENUE Illinois Institute of Technology
Stuart Building, Room 212, 10 West 31st Street Chicago
IL 60616; Contact Jennifer Keplinger at keplinger@iit.edu to confirm attendence
|
|
COLLEGE STATION: Texas A&M University
Wisenbaker Building (WERC), Room #049,
College Station, TX 77843;
979-845-8912
|
|
|
DALLAS: Winstead PC
5400 Renaissance Tower, 1201 Elm Street
Dallas, TX 75270; 214-745-5400
|
|
EL PASO: El Paso Community College
9050 Viscount, Bldg. B
El Paso, TX 79925
|
|
|
HOUSTON: Winstead PC
1100 JPMorgan Chase Tower
600 Travis Street
Houston, TX 77002
713-650-8400
|
|
|
SAN ANTONIO: Winstead PC
700 N. St Mary St., Ste 1900
San Antonio, TX 78205
210-277-6800
|
|
|
THE WOODLANDS: Winstead PC
600 Town Center One
1450 Lake Robbins Drive
The Woodlands, TX 77380
281-681-5900
|
|
|
Program begins at 11:30am [CDT] with a complimentary lunch provided by Winstead PC.
Presentation begins at 12:00pm.
Event Coordinators:
Richard Fink 512-339-5020x130 dfink@appliednanotech.net
Max Roundhill 512-339-5020x120 roundhill@appliednanotech.net
Chairman: Dr. Zvi Yaniv
Registration deadline is Friday, November 14 at 5:00 PM Central.
To register, please send an email to Nina Shuvalov
NShuvalov@appliednanotech.net with your preferred attendance location.
|
| |
|
|
NANOMATERIALS APPLICATION CENTER
Walt Trybula, Ph.D.
Director
Texas State University
San Marcos, TX
(512) 245-6062
|
DVDs of selected presentations from previous
speakers are available for a small fee (contact
Max Roundhill mroundhill@appliednanotech.net)
NanoExpress, a monthly email newsletter, is
devoted to providing information on technological
advances, applications, and business news to
nanotechnology professionals. To subscribe, go to
the web link
http://www.txstate.edu/nac/nanoexpress.htmlx
Return to the Schedule Page
|
|
